184 related articles for article (PubMed ID: 29953923)
1. The soluble form of LOTUS inhibits Nogo receptor type 1-mediated signaling induced by B lymphocyte stimulator and chondroitin sulfate proteoglycans.
Kawakami Y; Saito Y; Nakagawa R; Kurihara Y; Takei K
Neurosci Lett; 2018 Sep; 683():61-68. PubMed ID: 29953923
[TBL] [Abstract][Full Text] [Related]
2. The Soluble Form of LOTUS inhibits Nogo Receptor-Mediated Signaling by Interfering with the Interaction Between Nogo Receptor Type 1 and p75 Neurotrophin Receptor.
Kawakami Y; Kurihara Y; Saito Y; Fujita Y; Yamashita T; Takei K
J Neurosci; 2018 Mar; 38(10):2589-2604. PubMed ID: 29440387
[TBL] [Abstract][Full Text] [Related]
3. LOTUS suppresses axon growth inhibition by blocking interaction between Nogo receptor-1 and all four types of its ligand.
Kurihara Y; Iketani M; Ito H; Nishiyama K; Sakakibara Y; Goshima Y; Takei K
Mol Cell Neurosci; 2014 Jul; 61():211-8. PubMed ID: 25034269
[TBL] [Abstract][Full Text] [Related]
4. Blockade of chondroitin sulfate proteoglycans-induced axonal growth inhibition by LOTUS.
Kurihara Y; Saito Y; Takei K
Neuroscience; 2017 Jul; 356():265-274. PubMed ID: 28571719
[TBL] [Abstract][Full Text] [Related]
5. Nogo receptor antagonist LOTUS exerts suppression on axonal growth-inhibiting receptor PIR-B.
Kurihara Y; Takai T; Takei K
J Neurochem; 2020 Nov; 155(3):285-299. PubMed ID: 32201946
[TBL] [Abstract][Full Text] [Related]
6. The carboxyl-terminal region of Crtac1B/LOTUS acts as a functional domain in endogenous antagonism to Nogo receptor-1.
Kurihara Y; Arie Y; Iketani M; Ito H; Nishiyama K; Sato Y; Nakamura F; Mizuki N; Goshima Y; Takei K
Biochem Biophys Res Commun; 2012 Feb; 418(2):390-5. PubMed ID: 22281491
[TBL] [Abstract][Full Text] [Related]
7. The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors.
Chivatakarn O; Kaneko S; He Z; Tessier-Lavigne M; Giger RJ
J Neurosci; 2007 Jul; 27(27):7117-24. PubMed ID: 17611264
[TBL] [Abstract][Full Text] [Related]
8. Axonal branching in lateral olfactory tract is promoted by Nogo signaling.
Iketani M; Yokoyama T; Kurihara Y; Strittmatter SM; Goshima Y; Kawahara N; Takei K
Sci Rep; 2016 Dec; 6():39586. PubMed ID: 28000762
[TBL] [Abstract][Full Text] [Related]
9. Cartilage acidic protein-1B (LOTUS), an endogenous Nogo receptor antagonist for axon tract formation.
Sato Y; Iketani M; Kurihara Y; Yamaguchi M; Yamashita N; Nakamura F; Arie Y; Kawasaki T; Hirata T; Abe T; Kiyonari H; Strittmatter SM; Goshima Y; Takei K
Science; 2011 Aug; 333(6043):769-73. PubMed ID: 21817055
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition.
Robak LA; Venkatesh K; Lee H; Raiker SJ; Duan Y; Lee-Osbourne J; Hofer T; Mage RG; Rader C; Giger RJ
J Neurosci; 2009 May; 29(18):5768-83. PubMed ID: 19420245
[TBL] [Abstract][Full Text] [Related]
11. Versican V2 and the central inhibitory domain of Nogo-A inhibit neurite growth via p75NTR/NgR-independent pathways that converge at RhoA.
Schweigreiter R; Walmsley AR; Niederöst B; Zimmermann DR; Oertle T; Casademunt E; Frentzel S; Dechant G; Mir A; Bandtlow CE
Mol Cell Neurosci; 2004 Oct; 27(2):163-74. PubMed ID: 15485772
[TBL] [Abstract][Full Text] [Related]
12. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans.
Dickendesher TL; Baldwin KT; Mironova YA; Koriyama Y; Raiker SJ; Askew KL; Wood A; Geoffroy CG; Zheng B; Liepmann CD; Katagiri Y; Benowitz LI; Geller HM; Giger RJ
Nat Neurosci; 2012 Mar; 15(5):703-12. PubMed ID: 22406547
[TBL] [Abstract][Full Text] [Related]
13. Oligodendrocyte-myelin glycoprotein and Nogo negatively regulate activity-dependent synaptic plasticity.
Raiker SJ; Lee H; Baldwin KT; Duan Y; Shrager P; Giger RJ
J Neurosci; 2010 Sep; 30(37):12432-45. PubMed ID: 20844138
[TBL] [Abstract][Full Text] [Related]
14. Brain-derived neurotrophic factor (BDNF) induces antagonistic action to Nogo signaling by the upregulation of lateral olfactory tract usher substance (LOTUS) expression.
Matsubayashi J; Kawaguchi Y; Kawakami Y; Takei K
J Neurochem; 2023 Jan; 164(1):29-43. PubMed ID: 36448220
[TBL] [Abstract][Full Text] [Related]
15. The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein.
Venkatesh K; Chivatakarn O; Lee H; Joshi PS; Kantor DB; Newman BA; Mage R; Rader C; Giger RJ
J Neurosci; 2005 Jan; 25(4):808-22. PubMed ID: 15673660
[TBL] [Abstract][Full Text] [Related]
16. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp.
Wang KC; Kim JA; Sivasankaran R; Segal R; He Z
Nature; 2002 Nov; 420(6911):74-8. PubMed ID: 12422217
[TBL] [Abstract][Full Text] [Related]
17. Characterization of myelin ligand complexes with neuronal Nogo-66 receptor family members.
Laurén J; Hu F; Chin J; Liao J; Airaksinen MS; Strittmatter SM
J Biol Chem; 2007 Feb; 282(8):5715-25. PubMed ID: 17189258
[TBL] [Abstract][Full Text] [Related]
18. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth.
Wang KC; Koprivica V; Kim JA; Sivasankaran R; Guo Y; Neve RL; He Z
Nature; 2002 Jun; 417(6892):941-4. PubMed ID: 12068310
[TBL] [Abstract][Full Text] [Related]
19. CNS axon regeneration inhibitors stimulate an immediate early gene response via MAP kinase-SRF signaling.
Stern S; Knöll B
Mol Brain; 2014 Nov; 7():86. PubMed ID: 25406759
[TBL] [Abstract][Full Text] [Related]
20. Differential expression patterns of messenger RNAs encoding Nogo receptors and their ligands in the rat central nervous system.
Funahashi S; Hasegawa T; Nagano A; Sato K
J Comp Neurol; 2008 Jan; 506(1):141-60. PubMed ID: 17990276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
